SEC Form 4 · accession 0001209191-16-093488
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lee Zane
Officer — SVP and Chief Medical Officer
Period of report
Jan 22, 2016
Accepted (ET)
Jan 25, 2016 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 22, 2016 | M | 11,800 | $7.55 | A | 39,081 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $7.55 | Jan 22, 2016 | M | 11,800 | D | — | Aug 20, 2020 | Common Stock | 11,800 | 0 | D |
Explanation of responses
- F1This option is fully vested and exercisable.